◆ NeutralCYTK
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
GlobeNewswire Inc.·
Cytokinetics announced that its management team will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026. The company will discuss its cardiovascular biopharmaceutical pipeline, including MYQORZO® (aficamten) for obstructive hypertrophic cardiomyopathy and ongoing development of omecamtiv mecarbil and ulacamten for heart failure treatments.
Read Full Article at GlobeNewswire Inc. →